{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/herpes-simplex-oral/prescribing-information/oral-antiviral-drugs/","result":{"pageContext":{"chapter":{"id":"eeff86e7-c71a-5781-a929-0698c0bcfc16","slug":"oral-antiviral-drugs","fullItemName":"Oral antiviral drugs","depth":2,"htmlHeader":"<!-- begin field 854c445c-79f2-4e3f-b254-ded6da5c6a0d --><h2>Oral antiviral drugs</h2><!-- end field 854c445c-79f2-4e3f-b254-ded6da5c6a0d -->","summary":"","htmlStringContent":"<!-- begin item b3fa03fe-ddd5-4df1-8f18-b4edaa217e9b --><!-- begin field 53b2e800-d18e-4fe9-a7ea-03587173aa8a --><p>Oral antiviral drugs are indicated within 5 days of the start of the episode, while new lesions are still forming, or if systemic symptoms persist.</p><p><strong>Aciclovir</strong> is licensed for the treatment of herpes simplex infections of the skin and mucous membranes, including oral herpes gingivostomatitis. Advise that it should be started at the onset of any prodromal symptoms or signs.</p><ul><li>Adults and children aged 2–18 years — prescribe aciclovir 400 mgs three times a day<em>.</em> Prescribe a longer course, depending on clinical judgement, if new lesions appear during treatment, or if healing is incomplete.</li><li>Children aged 1 month to under 2 years — prescribe 100 mg five times a day (usually every 4 hours while awake) for 5 days. Prescribe a longer course, depending on clinical judgement, if new lesions appear during treatment, or if healing is incomplete.</li><li>Immunocompromised people — prescribe double the standard doses for healthy people.</li></ul><p><strong>Valaciclovir</strong> is licensed for the treatment of herpes simplex infections of the skin and mucous membranes. Advise it should be started at the onset of any prodromal symptoms or signs.</p><ul><li>Adults and children aged 12 years and over — prescribe 500 mg twice a day for 5 days for primary infections, which may be extended to 10 days if new lesions appear during treatment, or if healing is incomplete. Prescribe 500 mg twice a day for 3–5 days for recurrent episodes. An alternative regime for herpes labialis is 2000 mg twice a day for one day only. The second dose should be taken about 12 hours after the first dose.</li><li>Immunocompromised people — prescribe 1000 mg twice a day for up to 10 days for primary infections, and for 5–10 days for recurrent episodes.</li><li>Note: valaciclovir is not licensed for use in children under 12 years of age.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">ABPI, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">BNF 72, 2016</a>]</p><!-- end field 53b2e800-d18e-4fe9-a7ea-03587173aa8a --><!-- end item b3fa03fe-ddd5-4df1-8f18-b4edaa217e9b -->","topic":{"id":"401dad14-da6a-5b54-bb3d-2cfea5661d4b","topicId":"5f875f0c-db78-44fb-b672-bd54c9216205","topicName":"Herpes simplex - oral","slug":"herpes-simplex-oral","lastRevised":"Last revised in October 2016","chapters":[{"id":"2106bbf3-357c-5e99-8faf-4898c1ca935e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"83c52d0f-97ef-5a31-8ff4-41d30aff63ad","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"88707caf-63e9-5b1e-bd0d-adca6b1e4d1b","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0b1ea486-a30d-554a-87c3-68b2a981d26d","slug":"changes","fullItemName":"Changes"},{"id":"96fd5acc-0417-54f9-8185-fd7234a33908","slug":"update","fullItemName":"Update"}]},{"id":"56d4e2ce-1a2c-5bbf-9a02-d7ec1fe80537","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"abbdfc66-bff5-502d-ad7d-32c81000d0f2","slug":"goals","fullItemName":"Goals"},{"id":"b3a9824a-ae33-5fa9-81e7-a932b005c125","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f2bb54c7-b5b0-5b30-a704-921dce3f32c9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d3f7ec4d-ecc0-5956-b6b6-22c492e1122f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9944dadf-7acf-5f24-8f20-c050c044edba","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"425c65b2-de3b-5863-b73c-72199baee6f1","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"5749e0ab-cd7c-5a50-bc2c-ef816e9599c2","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"1d630313-1e41-59ae-8ae9-5cd26302276f","slug":"definition","fullItemName":"Definition"},{"id":"31a0a436-27cb-58e7-949b-76fb6dbd9c54","slug":"transmission","fullItemName":"Transmission"},{"id":"98ffdaac-76d5-54c1-93f5-7dd4a2f9148b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"bf160e19-7acf-5ed0-9c7a-be8eeb5b5d1c","slug":"complications","fullItemName":"Complications"},{"id":"739ee047-f37b-56ca-ae40-7c3875158ee6","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"bc2ab338-32ce-50dc-8b2b-3546b85d2d9f","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"78e575da-c305-5bf9-b61a-f062ae2c4eb5","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"e37bcee1-69de-5e61-9294-81ff5642fa57","slug":"assessment","fullItemName":"Assessment"},{"id":"ed37f634-077a-5cf4-880d-5d2e9e5e5d9c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"ca77797d-b745-54df-ae5b-ca78f5b20941","fullItemName":"Management","slug":"management","subChapters":[{"id":"3270af1a-6907-5c03-9ffb-c4d827c56103","slug":"herpes-labialis-gingivostomatitis","fullItemName":"Scenario: Herpes labialis and gingivostomatitis"}]},{"id":"059e9ce0-0874-50ea-b177-6ae9c92398c4","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8416d8f1-2061-51a1-b6ab-29d314b7738e","slug":"analgesia","fullItemName":"Analgesia"},{"id":"eeff86e7-c71a-5781-a929-0698c0bcfc16","slug":"oral-antiviral-drugs","fullItemName":"Oral antiviral drugs"}]},{"id":"3a06d913-863d-5a7d-a6ce-6f327e1db685","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"981bfc0e-bf2d-528d-a298-5ed824004d46","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d4db274b-f8f9-559e-8053-48f1712ad1f3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"1ee8a0ab-5883-561f-9aed-2524df466dfb","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1c48988f-4b5b-512c-90dc-8f7341fd9a0f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e1757009-f8a2-561e-9c49-0048e0c195b9","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"9fbce5d9-f27e-5f7c-8744-4b00ad58e71d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d5966d8c-2014-541a-bd9b-fbab33577d44","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"059e9ce0-0874-50ea-b177-6ae9c92398c4","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"1601c162-47cb-5ec3-8b20-0288e33c74e1","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 569cf5fe-9896-45c7-9219-e9762d5b48c7 --><h3>Adverse effects</h3><!-- end field 569cf5fe-9896-45c7-9219-e9762d5b48c7 -->","summary":"","htmlStringContent":"<!-- begin item 4d3ba51c-fa38-4a26-92de-62b974c66dff --><!-- begin field 71a7db20-d112-4a86-a57e-c3905fa9e150 --><ul><li><p><strong>Aciclovir and valaciclovir are generally well tolerated.</strong></p><ul><li><p>They may cause headaches, fatigue, dizziness, nausea, vomiting, diarrhoea, and abdominal pain, itch, and rash (including photosensitivity and urticaria).</p></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">ABPI, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">BNF 72, 2016</a>]</p><!-- end field 71a7db20-d112-4a86-a57e-c3905fa9e150 --><!-- end item 4d3ba51c-fa38-4a26-92de-62b974c66dff -->","subChapters":[]},{"id":"ec55334b-8063-53c9-a546-0b4d5639f79d","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field a9acce08-a2db-4579-8094-aafc8b0f2bf3 --><h3>Contraindications and cautions</h3><!-- end field a9acce08-a2db-4579-8094-aafc8b0f2bf3 -->","summary":"","htmlStringContent":"<!-- begin item dce82ac6-e13e-4f58-8bf6-235929e9dfa7 --><!-- begin field bb215909-8a05-4e05-b957-04b8d461b9f7 --><ul><li><strong>Do not prescribe aciclovir</strong> to a person with a known hypersensitivity to aciclovir, valaciclovir, or any of the expients.</li><li><strong>Prescribe aciclovir with caution</strong> to a person who:<ul><li>Is elderly — dose reduction may be needed depending on risk of renal impairment.</li><li>Has an underlying neurological abnormality.</li><li>Has severe liver or electrolyte abnormalities.</li><li>Has significant hypoxia.</li><li>Has renal impairment — advise the person to maintain adequate fluid intake, as aciclovir is eliminated by renal clearance. Reduce the dose to 200 mg every 12 hours if the estimated glomerular filtration rate (eGFR) is less than 10 mL/min/1.73 m<sup>2</sup>.</li><li>Is breastfeeding — aciclovir has been detected in breast milk when given at oral doses to treat herpes simplex infections. It is not known to be harmful, but the manufacturer advises caution.</li></ul></li><li><strong>Do not prescribe valaciclovir</strong> to a person with a known hypersensitivity to valaciclovir.</li><li><strong>Prescribe valaciclovir with caution</strong> to a person who:<ul><li>Is elderly — dose reduction may be needed depending on risk of renal impairment.</li><li>Has hepatic impairment.</li><li>Has renal impairment — advise the person to maintain adequate fluid intake.<ul><li>If the eGFR is 30–50 mL/min/1.73 m<sup>2</sup>, prescribe 1000 mg initially, then 1000 mg 12 hours later.</li><li>If the eGFR is 10–30 mL/min/1.73 m<sup>2</sup>, prescribe 500 mg initially, then 500 mg 12 hours later.</li><li>If the eGFR is less than 10 mL/min/1.73 m<sup>2</sup>, prescribe 500 mg as a single dose.</li></ul></li><li>Is breastfeeding — valaciclovir has been detected in breast milk when given at oral doses to treat herpes simplex infections. It is not known to be harmful, but the manufacturer advises caution.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">ABPI, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">BNF 72, 2016</a>]</p><!-- end field bb215909-8a05-4e05-b957-04b8d461b9f7 --><!-- end item dce82ac6-e13e-4f58-8bf6-235929e9dfa7 -->","subChapters":[]},{"id":"46a7c3cb-b1bd-5c20-b461-5cb8209cb205","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 05ac33c3-ad2a-4108-9828-a5197d077576 --><h3>Drug interactions</h3><!-- end field 05ac33c3-ad2a-4108-9828-a5197d077576 -->","summary":"","htmlStringContent":"<!-- begin item b2a33b3f-5cad-4b71-a621-5a30684f2a47 --><!-- begin field abeac257-de2b-406e-bb7b-11592c7b3b2a --><ul><li><strong>No clinically significant drug interactions have been reported for aciclovir and valaciclovir, but the following have been reported as possible drug interactions:</strong><ul><li>The risk of renal impairment is increased by the concomitant use of other nephrotoxic drugs with aciclovir or valaciclovir.</li><li>Aminophylline and theophylline — aciclovir or valaciclovir may increase plasma aminophylline and theophylline levels.</li><li>Ciclosporin — increased risk of nephrotoxicity when aciclovir or valaciclovir given with ciclosporin.</li><li>Mycophenalate — plasma concentration of aciclovir or valaciclovir increased by mycophenolate.</li><li>Tacrolimus — possible increased risk of nephrotoxicity when aciclovir or valaciclovir given with tacrolimus.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">ABPI, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/herpes-simplex-oral/references/\">BNF 72, 2016</a>]</p><!-- end field abeac257-de2b-406e-bb7b-11592c7b3b2a --><!-- end item b2a33b3f-5cad-4b71-a621-5a30684f2a47 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}